Syros Pharmaceuticals (NASDAQ: SYRS) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations and risk.
Insider & Institutional Ownership
58.0% of Syros Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.3% of BioMarin Pharmaceutical shares are owned by institutional investors. 33.6% of Syros Pharmaceuticals shares are owned by company insiders. Comparatively, 1.9% of BioMarin Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This is a summary of recent ratings and recommmendations for Syros Pharmaceuticals and BioMarin Pharmaceutical, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Syros Pharmaceuticals currently has a consensus target price of $26.14, suggesting a potential upside of 174.58%. BioMarin Pharmaceutical has a consensus target price of $114.55, suggesting a potential upside of 31.09%. Given Syros Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Syros Pharmaceuticals is more favorable than BioMarin Pharmaceutical.
Earnings & Valuation
This table compares Syros Pharmaceuticals and BioMarin Pharmaceutical’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Syros Pharmaceuticals||$320,000.00||782.43||-$47.74 million||($1.74)||-5.47|
|BioMarin Pharmaceutical||$1.12 billion||13.74||-$630.21 million||($0.90)||-97.09|
Syros Pharmaceuticals has higher earnings, but lower revenue than BioMarin Pharmaceutical. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This table compares Syros Pharmaceuticals and BioMarin Pharmaceutical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.